INDICATIONS
Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

CONTRAINDICATIONS
Do not administer DEFINITY® to patients with known or suspected right-to-left, bi-directional or transient right-to-left cardiac shunts, by intra-arterial injection, or to patients with known hypersensitivity to perflutren.

IMPORTANT SAFETY INFORMATION

WARNING: Serious Cardiopulmonary Reactions
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration [See WARNINGS AND PRECAUTIONS (5.1)]. Most serious reactions occur within 30 minutes of administration.

• Assess all patients for the presence of any condition that precludes DEFINITY® administration [See CONTRAINDICATIONS (4)].
• Always have resuscitation equipment and trained personnel readily available.

In postmarketing use, rare but serious cardiopulmonary or anaphylactoid reactions have been reported during or shortly following perflutren-containing microsphere administration [See ADVERSE REACTIONS (6)]. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions [See Postmarketing Experience (6.2)]. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying cardiopulmonary disease.

The DEFINITY® Difference
A proven diagnostic advantage that optimizes outcomes, patient management, and cost-effectiveness1

• Impacts cardiac diagnosis1
• Avoids additional diagnostic procedures1
• Alters patient management decisions1
• Reduces resource utilization and per-patient expense1

More than 5.6 million echo studies have been performed with DEFINITY®7

Please see brief summary on the next page, including boxed WARNING regarding serious cardiopulmonary reactions.

Visit DEFINITYimaging.com

DEF_JASE_Ad_v6_v19Feb16.indd   1
2/19/16   4:44 PM